| DAY 1 | Room 3A | Room 3B | Hall 1B | Hall 1C | Room 11B - Workshop | Careers Zone, Main Exhibition Hall | |
| 8:00 |
Event Registration |
|
|
|
|
Early Career Professional Welcome
08:00 (45 mins)
Lisa Stott, Sosei Heptares
|
8:00: |
| 8:05: |
|
|
|
|
8:05: |
| 8:10: |
|
|
|
|
8:10: |
| 8:15: |
|
|
|
|
8:15: |
| 8:20: |
|
|
|
|
8:20: |
| 8:25: |
|
|
|
|
8:25: |
| 8:30: |
|
|
|
|
8:30: |
| 8:35: |
|
|
|
|
8:35: |
| 8:40: |
|
|
|
|
8:40: |
| 8:45: |
ELRIG - Annual Review - Visons & Values
08:45 (10 mins)
Melanie Leveridge, GSK
ELRIG - Equality, Diversity & Inclusion Guiding Principals
08:55 (5 mins)
Clare Viney, Vitae
ELRIG - Lifetime Achievement Award - A Career In Drug Discovery
09:00 (20 mins)
Steve Rees, AstraZeneca
|
|
|
|
|
|
8:45: |
| 8:50: |
|
|
|
|
|
8:50: |
| 8:55: |
|
|
|
|
|
8:55: |
| 9:00 |
|
|
|
|
|
9:00: |
| 9:05: |
|
|
|
|
|
9:05: |
| 9:10: |
|
|
|
|
|
9:10: |
| 9:15: |
|
|
|
|
|
9:15: |
| 9:20: |
|
|
|
|
|
9:20: |
| 9:25: |
|
|
|
|
|
9:25: |
| 9:30: |
|
|
|
|
|
9:30: |
| 9:35: |
|
|
|
|
|
9:35: |
| 9:40: |
|
|
|
|
|
9:40: |
| 9:45: |
|
|
|
|
|
9:45: |
| 9:50: |
|
|
|
|
|
9:50: |
| 9:55: |
|
|
|
|
|
9:55: |
| 10:00 |
|
|
|
|
|
10:00 |
| 10:05 |
|
|
|
|
|
10:05 |
| 10:10 |
Refreshment Break |
|
|
|
|
|
10:10 |
| 10:15 |
|
|
|
|
|
10:15 |
| 10:20 |
|
|
|
|
|
10:20 |
| 10:25 |
|
|
|
|
|
10:25 |
| 10:30 |
|
|
|
|
|
10:30 |
| 10:35 |
|
|
|
|
|
10:35 |
| 10:40 |
|
|
|
|
|
10:40 |
| 10:45 |
|
|
|
|
|
10:45 |
| 10:50 |
|
|
|
|
Gaining a career in industry: Learning tips and tricks from the inside
10:50 (60 mins)
Allan Jordan, Sygnature Discovery
|
|
10:50 |
| 10:55 |
|
10:55 |
| 11:00 |
Neuropilin-1 facilitates SARS-CoV2 cell entry and infectivity
11:00 (30 mins)
Maria Anastasina, University of Helsinki
|
Q-POCTM, a paradigm shift in rapid multiplex molecular diagnostics
11:00 (30 mins)
Jonathan OHalloran, QuantumDx
|
Discovery of risdiplam (evrysdi) - A medicine for the treatment of spinal muscular atrophy
11:00 (30 mins)
Hasane Ratni , F. Hoffmam-La Roche
|
Alzheimer’s Research UK and its support for translational research.
11:00 (30 mins)
Sara Imarisio, ARUK
|
|
11:00 |
| 11:05 |
|
11:05 |
| 11:10 |
|
11:10 |
| 11:15 |
|
11:15 |
| 11:20 |
|
11:20 |
| 11:25 |
|
11:25 |
| 11:30 |
|
11:30 |
| 11:35 |
|
11:35 |
| 11:40 |
|
11:40 |
| 11:45 |
|
11:45 |
| 11:50 |
|
|
11:50 |
| 11:55 |
|
|
11:55 |
| 12:00 |
Functional analysis of Bartonella pathogenicity factors might contribute to novel therapeutic concepts
12:00 (30 mins)
Volkhard Kempf , Goethe University of Frankfurt am Main
|
A luminescent reporter cell line for authentic SARS-CoV-2 infection and neutralising antibody activity
12:00 (30 mins)
Nick Matheson, University of Cambridge
|
mRNA Lightning platform for the discovery of selective small molecule mRNA regulatory drugs
12:00 (30 mins)
Iris Alroy, Anima Biotech
|
Identification of tool compounds targeting the SRSF1-dependent nuclear export of pathological C9ORF72-repeat transcripts
12:00 (30 mins)
Lianne Van Beek, CRL Tennore Ramesh, Sheffield Institute for Translational Neuroscience (SITraN)
|
|
|
12:00 |
| 12:05 |
|
|
12:05 |
| 12:10 |
|
|
12:10 |
| 12:15 |
|
|
12:15 |
| 12:20 |
|
|
12:20 |
| 12:25 |
|
|
12:25 |
| 12:30 |
Refreshment Break |
|
|
|
Inclusive research and experimental design
12:30 (60 mins)
Lilian Hunt, EDIS, Wellcome Trust
|
|
12:30 |
| 12:35 |
|
|
|
|
12:35 |
| 12:40 |
|
|
|
|
12:40 |
| 12:45 |
|
|
|
|
12:45 |
| 12:50 |
|
|
|
|
12:50 |
| 12:55 |
|
|
|
|
12:55 |
| 1:00 |
|
|
|
|
1:00: |
| 1:05: |
|
|
|
|
1:05: |
| 1:10: |
|
|
|
|
1:10: |
| 1:15: |
|
|
|
|
1:15: |
| 1:20: |
|
|
|
|
1:20: |
| 1:25: |
|
|
|
|
1:25: |
| 1:30: |
|
|
|
|
|
1:30: |
| 1:35: |
|
|
|
|
|
1:35: |
| 1:40: |
|
|
|
|
|
1:40: |
| 1:45: |
|
|
|
|
|
1:45: |
| 1:50: |
|
|
|
|
|
1:50: |
| 1:55: |
|
|
|
|
|
1:55: |
| 2:00 |
Targeting the human RED-SMU1 splicing complex as a basis for host-directed anti-influenza therapy
14:00 (30 mins)
Nadia Naffakh, Institut Pasteur, CNRS
|
Diagnostics for epidemics, pandemics and neglected tropical disease
14:00 (30 mins)
Emily Adams, Liverpool School of Tropical Medicine and Mologic
|
Dynamic RNAs and Structure-Guided Small Molecule Drug Discovery
14:00 (30 mins)
Isaac Kimsey, Nymirum Yang Zheng, Nymirum
|
Small molecule inhibitors of carboxylesterase Notum to potentiate Wnt signalling
14:00 (30 mins)
Nicky Willis, UCL DDI
|
Exceptional Science Presentations: How to Effectively Communicate the Value of Your Work
14:00 (45 mins)
Anita Ramanathan, Word Cortex
|
|
2:00: |
| 2:05: |
|
2:05: |
| 2:10: |
|
2:10: |
| 2:15: |
|
2:15: |
| 2:20: |
|
2:20: |
| 2:25: |
|
2:25: |
| 2:30: |
|
2:30: |
| 2:35: |
Tecan UK Ltd
|
|
2:35: |
| 2:40: |
|
|
2:40: |
| 2:45: |
Studies of the membrane-bound pyrophosphatase as a potential drug target against protist parasites
14:45 (30 mins)
Keni Vidilaseris, University of Helsinki
|
EMERGING DIAGNOSTIC TECHNOLOGIES IN CLINICAL MICROBIOLOGY
14:45 (30 mins)
Alex Van Belkum, Biomeirieux
|
Small activating RNAs from concept to Phase 2 clinical trial
14:45 (30 mins)
Vikash Reebye Nagy Habib , MiNA Therapeutics
|
Development of eIF2B modulators for the treatment of neurodegenerative disease
14:45 (30 mins)
Duncan Scott, Alborada Drug Discovery Institute, Cambridge
|
|
|
2:45: |
| 2:50: |
|
|
2:50: |
| 2:55: |
|
|
2:55: |
| 3:00 |
|
|
3:00: |
| 3:05: |
|
|
3:05: |
| 3:10: |
|
|
3:10: |
| 3:15: |
Refreshment Break |
|
|
|
|
|
3:15: |
| 3:20: |
|
|
|
|
|
3:20: |
| 3:25: |
|
|
|
|
|
3:25: |
| 3:30: |
|
|
|
|
|
3:30: |
| 3:35: |
|
|
|
|
|
3:35: |
| 3:40: |
|
|
|
|
|
3:40: |
| 3:45: |
Developing inhibitors that block adhesin-collagen interactions
15:45 (30 mins)
Dirk Linke, University of Oslo
|
Computer literate? Novel AI based reading of lateral flow devices
15:45 (30 mins)
Daniel Wise, Excalibur Healthcare
|
Drugging RNA Modifying Enzymes – METTL3 Inhibitors as a novel therapeutic strategy for Acute Myeloid Leukemia
15:45 (30 mins)
David Hardick, Storm Therapeutics Konstantinos Tzelepis , The Milner Therapeutics Institute
|
Gene editing to treat expanded CAG/CTG repeat disorders
15:45 (30 mins)
Vincent Dion, Cardiff Dementia Research Institute
|
|
|
3:45: |
| 3:50: |
|
3:50: |
| 3:55: |
|
3:55: |
| 4:00 |
|
4:00: |
| 4:05: |
|
4:05: |
| 4:10: |
|
4:10: |
| 4:15: |
|
|
4:15: |
| 4:20: |
|
4:20: |
| 4:25: |
|
4:25: |
| 4:30: |
Inhibition of bacterial virulence as an alternative to antibiotic treatment: Pseudomonas aeruginosa elastase as a target for antivirulence therapy
16:30 (30 mins)
Martin Everett, Antabio
|
How to build a mobile lab for genomic surveillance of viral outbreaks
16:30 (30 mins)
Joshua Quick, Institute of Microbiology and infection, University of Birmingham
|
X-reactivation as an approach to treating Rett Syndrome
16:30 (30 mins)
Jeannie Lee, Harvard
|
Novel Therapeutic Targets for Treatment of Neurodegeneration
16:30 (30 mins)
Paul Brennan, Oxford DDI
|
|
4:30: |
| 4:35: |
|
4:35: |
| 4:40: |
|
4:40: |
| 4:45: |
|
|
4:45: |
| 4:50: |
|
|
4:50: |
| 4:55: |
|
|
4:55: |
| 5:00 |
Networking & Posters |
|
|
|
|
|
5:00: |
| 5:05: |
|
|
|
|
|
5:05: |
| 5:10: |
|
|
|
|
|
5:10: |
| 5:15: |
|
|
|
|
|
5:15: |
| 5:20: |
|
|
|
|
|
5:20: |
| 5:25: |
|
|
|
|
|
5:25: |
| 5:30: |
|
|
|
|
|
5:30: |
| 5:35: |
|
|
|
|
|
5:35: |
| 5:40: |
|
|
|
|
|
5:40: |
| 5:45: |
|
|
|
|
|
5:45: |
| 5:50: |
|
|
|
|
|
5:50: |
| 5:55: |
|
|
|
|
|
5:55: |
| 6:00 |
|
|
|
|
|
6:00: |
| 6:05: |
|
|
|
|
|
6:05: |
| 6:10: |
|
|
|
|
|
6:10: |
| 6:15: |
|
|
|
|
|
6:15: |
| 6:20: |
|
|
|
|
|
6:20: |
| 6:25: |
|
|
|
|
|
6:25: |
| 6:30: |
|
|
|
|
|
6:30: |
| 6:35: |
|
|
|
|
|
6:35: |
| 6:40: |
|
|
|
|
|
6:40: |
| 6:45: |
|
|
|
|
|
6:45: |
| 6:50: |
|
|
|
|
|
6:50: |
| 6:55: |
|
|
|
|
|
6:55: |
| 7:00 |
|
|
|
|
|
|
7:00: |
Print
